Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


APAC Podcast: Virus Industry Impact, China Vaccines, Remdesivir Deals, Korea SitRep

Executive Summary

Join the Pink Sheet and Scrip's Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.

In the third in a popular new series of podcasts, the Asia-based content team for Scrip and the Pink Sheet dissect some of the major events shaping the regional pharma industry over the past few weeks. Unsurprisingly, the coronavirus outbreak remains top of the list.

Join Anju Ghangurde and Vibha Ravi in Mumbai, Brian Yang in Beijing, Jung Won Shin in Seoul and Ian Haydock in Tokyo for a top-line overview of selected key developments.



How Has The Pandemic Played Out in Company Earnings?

Major Indian and Japanese companies have now reported their annual results for the fiscal year ended 31 March, the end of which overlapped with the full emergence of the virus. Anju and Ian look at the varied business impact so far and what the rest of the year might hold. Are there any common themes emerging?

The Latest In China Vaccine Developments

Multiple Chinese companies have emerged among the global front-runners in the development of a possible vaccine against SARS-CoV-2. Brian takes us on a tour of local and international R&D developments in the field, and some of the challenges facing developers.  (Starts at 11’30’’)

What Does Gilead’s Remdesivir Licensing Deal Mean For Prices And Access?

Gilead’s investigational antiviral remdesivir has emerged as a potential existing drug treatment, although clear evidence of its efficacy and safety is still emerging. The US firm recently signed a no-royalty deal with multiple companies in India and Vibha breaks down what this might mean for the production, pricing and global access of the drug. (Starts at 18’10’’)

How Is Korea Coping With The Outbreak?

South Korea has received global praise for its adroit handling of the pandemic, although it is now facing challenges from the emergence of cluster outbreak after reopening. Meanwhile, the local pharma industry has responded with R&D into both drugs and vaccines. Jung Won explains these issues in her on-the-ground situation update. (Starts at 27'00")

Related Content

(Also see "With Eye On China, India Tightens Foreign Investment Vetting" - Pink Sheet, 22 Apr, 2020.)

(Also see "Global Supply Chain In Historic Upheaval As 'De-China' Trend Marches On" - Pink Sheet, 28 May, 2020.)

(Also see "How Was Korea Different In Handling COVID-19 Situation?" - Pink Sheet, 15 May, 2020.)


Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts